市场调查报告书
商品编码
1292426
微生物检测市场 - 按产品、按检测类型、按应用、按最终用途及预测,2023 - 2032年Microbiology Testing Market - By Product, By Test Type, By Application, By End-use & Forecast, 2023 - 2032 |
全球微生物学检测市场规模将在2023-2032年观察到可观的增长。对传染病如COVID-19、流感和其他疾病的认识不断提高,增加了对微生物检测的需求,以便早期发现疾病。全球各地的许多政府正在对诊断程序进行大量投资,以防止这些疾病的传播。此外,在这一领域经营的行业参与者正在创新新产品,以扩大他们的全球足迹,这将有助于在未来十年内改变市场动态。
整个微生物学检测市场根据产品、检测、应用、终端用途和地区来划分。
n、最终用途和地区划分。
就类型而言,到2032年,来自病毒部分的行业价值将录得显著收益。最近微生物学检测技术的进步已经改变了病毒性疾病的诊断。现代微生物检测技术,如聚合酶链式反应(PCR)和下一代测序(NGS),已经大大增强了病毒检测的灵敏度和特异性。这些方法甚至可以检测到微量的病毒遗传物质,从而能够在早期阶段识别病毒感染。
基于应用,到2032年,来自胃肠道疾病领域的微生物检测市场规模将大幅扩大。胃肠道疾病患病率的上升增加了对微生物学检测的需求。此外,新的创新,如微生物测试的下一代测序,推进了胃肠道问题的诊断。它提供了胃肠道微生物组的全面视图,并能检测已知和新型病原体,有助于诊断和了解胃肠道疾病。
基于终端用途,诊断中心部分的微生物检测市场价值将在2032年之前积累相当大的收益。熟练和有经验的医疗保健专业人员的高可用性,增加了诊断中心的病人数量。此外,对传染病认识的提高也增加了对这些设施的需求,进一步促进了该领域的扩张。许多诊断中心与医疗机构合作。
从区域角度看,欧洲微生物检测市场份额将在2023年至2032年以显著的复合年增长率增长。慢性疾病发病率的增长提高了该地区对微生物学检测的认识。此外,欧洲也是F. Hoffmann-La Roche Ltd、Merck KGaA等行业领先企业的所在地,它们不断关注产品创新。事实上,在2021年12月,罗氏公布了基于cobas(R)5800系统的传染病测试,这是一种新的分子实验室设备。
Global Microbiology Testing Market size will observe an appreciable growth over 2023-2032. Growing awareness about infectious diseases such as COVID-19, influenza, and others has increased the need for microbiology testing for early detection of the disease. Many governments across the globe are investing considerable amounts into diagnostic procedures for preventing the spread of these diseases. Moreover, industry players operating in this field are innovating new products to extend their global footprint, which will help transform market dynamics over the next ten years.
The overall microbiology testing market is divided based on product, test, applicatio
n, end-use, and region.
In terms of type, the industry value from the viral segment will register significant gains through 2032. Recent advancements in microbiology testing techniques have transformed the diagnosis of viral disorders. Modern microbiology testing techniques, such as Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), have significantly enhanced the sensitivity and specificity of viral detection. These methods can detect even trace amounts of viral genetic material, enabling the identification of viral infections in the early stages.
Based on application, the microbiology testing market size from the gastrointestinal diseases segment will expand substantially through 2032. Rising prevalence of gastrointestinal diseases has increased the need for microbiology testing. Moreover, novel innovations, such as next-generation sequencing in microbiology testing, have advanced the diagnosis of gastrointestinal issues. It provides a comprehensive view of the gastrointestinal microbiome and enables the detection of both known and novel pathogens, aiding in the diagnosis and understanding of gastrointestinal disorders.
Based on end-use, microbiology testing market value from the diagnostic centers segment will amass considerable gains through 2032. High availability of skilled and experienced healthcare professionals has increased patient footfall in diagnostic centers. Moreover, increasing awareness about infectious diseases has increased the demand for these facilities, further contributing to segment expansion. Many diagnostic centers work in collaboration with healthcare providers.
From the regional perspective, Europe microbiology testing market share will grow at a notable CAGR from 2023 to 2032. Growing prevalence of chronic disorders has increased awareness about microbiology testing in the region. Moreover, Europe is also home to leading industry players such as F. Hoffmann-La Roche Ltd, Merck KGaA, and others focusing on product innovations constantly. In fact, in December 2021, Roche unveiled the launch of infectious disease tests based on the cobas® 5800 System, which is a new molecular laboratory device.